ABOS Acumen Pharmaceuticals, Inc.

71

Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]

US | NASDAQ | Stock

Price
$5.75
Decreased by -3.20%
Dollar Volume
474.81 K
ADR%
9.11
Earnings Report Date (estimate)
Aug 15, 22 (N/A)
Market Cap.
235.32 M
Shares Float
13.38 M
Shares Outstanding
40.93 M
Beta
0.00
Price / Earnings
4.53
BPR
178.27
20D Range
5.19 6.83
50D Range
4.58 6.83
200D Range
3.02 10.95
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.26
Increased by +96.71%
 -0.23
Decreased by -13.04%
Aug 15, 22 -0.25 -0.24
Decreased by -4.17%
May 16, 22 -0.23 -0.17
Decreased by -35.29%
Nov 15, 21 -0.10 -0.17
Increased by +41.18%
Aug 16, 21 -7.91 -4.56
Decreased by -73.46%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
 -10.71 M
Decreased by -174.47%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
 -10.15 M
Increased by +83.46%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
 -9.13 M
Increased by +66.19%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by -100.00%
 -8.35 M
Decreased by -235.30%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by -100.00%
 -3.90 M
Decreased by -91.74%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by -100.00%
 -61.36 M
Decreased by -2.90 K%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00 - -27.00 M -
Decreased by N/A%
-
Sep 30, 20 730.00 K - -2.49 M -
Decreased by -341.10%
-
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.